Pre-symptomatic autoimmunity in rheumatoid arthritis: when does the disease start? by Raza, Karim & Buckley, Christopher
 
 
Pre-symptomatic autoimmunity in rheumatoid
arthritis: when does the disease start?
Raza, Karim; Buckley, Christopher
DOI:
10.1007/s00281-017-0620-6
License:
Creative Commons: Attribution (CC BY)
Document Version
Publisher's PDF, also known as Version of record
Citation for published version (Harvard):
Raza, K & Buckley, C 2017, 'Pre-symptomatic autoimmunity in rheumatoid arthritis: when does the disease
start?', Seminars in immunopathology, vol. 39, no. 4, pp. 423–435. https://doi.org/10.1007/s00281-017-0620-6
Link to publication on Research at Birmingham portal
General rights
Unless a licence is specified above, all rights (including copyright and moral rights) in this document are retained by the authors and/or the
copyright holders. The express permission of the copyright holder must be obtained for any use of this material other than for purposes
permitted by law.
•	Users may freely distribute the URL that is used to identify this publication.
•	Users may download and/or print one copy of the publication from the University of Birmingham research portal for the purpose of private
study or non-commercial research.
•	User may use extracts from the document in line with the concept of ‘fair dealing’ under the Copyright, Designs and Patents Act 1988 (?)
•	Users may not further distribute the material nor use it for the purposes of commercial gain.
Where a licence is displayed above, please note the terms and conditions of the licence govern your use of this document.
When citing, please reference the published version.
Take down policy
While the University of Birmingham exercises care and attention in making items available there are rare occasions when an item has been
uploaded in error or has been deemed to be commercially or otherwise sensitive.
If you believe that this is the case for this document, please contact UBIRA@lists.bham.ac.uk providing details and we will remove access to
the work immediately and investigate.
Download date: 01. Feb. 2019
REVIEW
Pre-symptomatic autoimmunity in rheumatoid arthritis: when
does the disease start?
Alexander Tracy1 & Christopher D. Buckley1,2 & Karim Raza1,2
Received: 28 February 2017 /Accepted: 2 March 2017
# The Author(s) 2017. This article is published with open access at Springerlink.com
Abstract It is well recognised that a state of autoimmunity,
in which immunological tolerance is broken, precedes the
development of symptoms in the majority of patients with
rheumatoid arthritis (RA). For individuals who will later
develop seropositive disease, this manifests as autoanti-
bodies directed against proteins that have undergone spe-
cific post-translational modifications. There is evidence
that the induction of this autoantibody response occurs at
peripheral extra-articular mucosal sites, such as the peri-
odontium and lung. In addition to their utility as diagnostic
markers, these autoantibodies may have a pathogenic role
that helps localise disease to the synovium. Alongside the
development of autoantibodies, other factors contributing
to pre-symptomatic autoimmunity may include dysbiosis
of the gastrointestinal tract, abnormal development of lym-
phoid tissue, and dysregulated autonomic and lipid-
mediated anti-inflammatory signalling. These factors com-
bine to skew the balance between pro-inflammatory and
anti-inflammatory signalling in a manner that is permissive
for the development of clinical arthritis. We present data to
support the concept that the transitions from at-risk states to
systemic autoimmunity and then to classifiable RA depend
on multiple Bswitches^. However, further prospective stud-
ies are necessary to define the molecular basis of these
switches and the specific features of pre-symptomatic au-
toimmunity, so that preventative treatments can be targeted
to individuals at high risk for RA. In this review, we ana-
lyse mechanisms that may contribute to the development of
autoimmunity in at-risk individuals and discuss the rela-
tionship between this pre-symptomatic state and subse-
quent development of RA.
Keywords Rheumatoid arthritis . Autoimmunity .
Inflammation . Autoantibodies
Introduction
Rheumatoid arthritis (RA) is a chronic inflammatory disease
characterised by symmetrical peripheral polyarthritis that can
lead to joint destruction and may be associated with extra-
articular features. There has been increasing interest in study-
ing its early stages with a view to modulating early pathogenic
processes to prevent RA development [1].
Rheumatoid arthritis results from a complex interplay be-
tween genetic and environmental factors. Arguably, the pres-
ence of these factors represents the earliest stage in the path-
ogenesis of RA. Because the aetiology of RA is multifactorial,
there has been some inconsistency in the terminology used to
describe its earliest stages. However, EULAR recommenda-
tions have provided a standard system for describing phases
leading up to the development of RAwhich we use throughout
this review [2, 3] (Table 1). Phases A to C can be considered
Bat-risk^ pre-symptomatic phases, while phases D and E rep-
resent symptomatic phases prior to the development of classi-
fiable RA.
In a large proportion of patients, RA is associated with
autoantibodies directed against post-translationally modi-
fied proteins/peptides including citrullinated (ACPAs),
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carbamylated (ACarPAs) and acetylated proteins/peptides
(AAPAs) [4, 5] and/or autoantibodies against the Fc portion
of IgG (rheumatoid factor, RF). Classically, ACPA-/RF-
positive patients are defined as seropositive and are known
to have a poor prognosis compared to seronegative patients
[6]. It is nowwell established from retrospective studies that
individuals may be seropositive, i.e. in phase C (EULAR
definition), for many years before developing symptoms of
inflammatory arthritis [7, 8]. More recently, these findings
have been extended to include anti-carbamylated protein
antibodies (ACarPAs) [9]. This represents important evi-
dence for a pre-symptomatic state of systemic autoimmuni-
ty associated with RA.
An additional line of evidence for pre-symptomatic immu-
nopathology comes from analysis of cytokine levels in blood
samples from pre-symptomatic individuals who later devel-
oped RA. This has demonstrated increased expression of
pro-inflammatory cytokines and chemokines compared to
control subjects [10]. Findings such as these indicate that path-
ological immune processes significantly predate the onset of
symptoms. Furthermore, there is magnetic resonance imaging
(MRI) evidence of subclinical joint inflammation in a subset
of individuals with arthralgia deemed suspicious for progres-
sion to RA [11]. Although histological analysis in pre-
symptomatic phases has not always demonstrated synovitis,
preliminary evidence is suggestive of subtle T-cell infiltration
preceding the signs and symptoms of arthritis [12]. Therefore,
even at the level of the joints, immune activation may occur
before it can be detected clinically.
Based on these lines of evidence, it is now widely ac-
cepted that there is a prolonged state of autoimmunity that
precedes symptom onset in RA. Using these immune char-
acteristics, we may be able to develop strategies to stratify
individuals for preventative interventions before develop-
ment of clinical disease. It may then prove possible to mod-
ulate the aetiological processes in such a way that prevents
progression to RA from phases A–E. However, a fuller un-
derstanding of pre-symptomatic autoimmunity is required
before this is possible. Here, we review what is currently
known on this subject and suggest how future research may
enhance our understanding.
We refer predominantly to studies of individuals before the
onset of symptoms of RA (phases A–C). However, some
studies of early disease mechanisms in RA have included
individuals in symptomatic at-risk disease stages (phases D
and E). This literature is discussed where it helps to inform
our understanding of very early disease mechanisms.
The majority of the literature cited in this review concerns
seropositive RA. This is because the study of at-risk seroneg-
ative populations in the pre-symptomatic stage is much more
challenging due to a lack of markers for risk of seronegative
RA. This is a significant limitation of the literature, and as a
result there has been very little work on early immune mech-
anisms of seronegative RA. However, it has been shown that a
population of patients with seronegative arthralgia deemed
prone to progression to RA have MRI evidence of subclinical
synovitis [13]. This is analogous to evidence from seroposi-
tive at-risk subjects. Therefore, it would be beneficial to un-
derstand early disease mechanisms in seronegative RA, where
the underlying immunopathology may be distinct from sero-
positive RA.
Predisposition to rheumatoid arthritis: how has
genetics informed our understanding of early
immunopathology?
In many individuals, the first stage of the development of RA
is the acquisition of genetic risk factors for the disease at
conception. Arguably, this represents the Bstart^ of the disease
process and accordingly represents phase A in EULAR termi-
nology. The study of genetic risk factors has contributed to our
understanding of the initial immunopathology of RA, for ex-
ample by emphasising the importance of T-cell activation in
seropositive disease. The best-studied genetic risk factors for
RA are specific variants at the HLA loci. The discovery that
many RA-associated alleles within theHLA-DRB1 gene share
a conserved amino acid sequence led Gregersen and col-
leagues to propose the Bshared epitope^ (SE) hypothesis
[14]. Interestingly, the presence of this amino acid sequence
in the MHC class II molecule confers an increased risk of anti-
citrullinated protein antibody (ACPA)-positive disease only
[15]. More recent work has suggested that five amino acid
positions explain most of the association between HLA alleles
and seropositive RA [16]. Two of these are within the classical
SE region. They are all located within peptide-binding
grooves on MHC class I or II molecules, indicating that poly-
morphisms may have a functional impact on antigen presen-
tation not only to CD4+ but also to CD8+ T-cells.
Furthermore, outside the HLA loci, other genetic risk factors
for RA involve genes that are implicated in T-cell activation
e.g. PTPN22, CTLA4 and STAT4 [17].
Epidemiological investigations have evaluated the stage at
which SE alleles impact the aetiology of seropositive RA. The
Table 1 Summary of EULAR terminology for phases of RA
development (adapted from [3])
Phase Definition
A Genetic risk factors for RA
B Environmental risk factors for RA
C Systemic autoimmunity associated with RA
D Symptoms without clinical arthritis
E Unclassified arthritis
F Rheumatoid arthritis
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presence of SE has been associated with ACPA positivity,
high ACPA concentrations and reactivity of ACPAs to multi-
ple, rather than single, autoantigens [18, 19]. SE alleles are
associated more strongly with ACPA-positive RA (phase F)
than with ACPA positivity in the absence of RA (phases C–E)
[19]. This suggests that SE alleles may play a greater role in
the switch from ACPA positivity to the development of RA
than in the initial induction of ACPA positivity.
The interaction of SE alleles with environmental factors is
controversial. A gene-environment interaction between SE
alleles and smoking was found for seropositive RA in a large
Swedish cohort [20] and in large Danish and Korean case-
control studies [21, 22]. However, this was only partially rep-
licated in three American cohorts [23]. There is also increasing
interest in the interplay between SE status and other environ-
mental factors, including omega-3 fatty acid consumption
levels, on RA risk. There is evidence from case-control and
prospective cohort studies suggesting that fish consumption is
inversely correlated with risk of RA [24], which may be me-
diated by an effect on omega-3 fatty acid levels. In a case-
control study, increased percentage of omega-3 fatty acids in
red blood cells (RBCs) was inversely correlated with RF and
ACPA positivity only in SE-positive participants [25]. The
mechanism behind this is unknown, but the authors speculate
that omega-3 fatty acids alter lipid rafts to change the confor-
mation and expression of MHC class II molecules. This could
have functional implications for autoantigen presentation [25].
While most genetic studies have focused on alleles associ-
ated with increased RA risk, there is an emerging role for
protective alleles. For example, in North European cohorts,
HLA-DRB1*13 has been associated with protection against
the development of ACPA-positive RA, but not from the de-
velopment of ACPA positivity in healthy subjects [26].
Furthermore, in participants with seropositive RA, HLA-
DRB1*13 is associated with reduced ACPA levels and a
narrower range of autoantigen recognition [26]. HLA-
DRB1*13 and HLA-DRB1 SE alleles seem to have inverse
but analogous effects, suggesting that they may influence the
same pathological pathway. The authors hypothesise that
HLA-DRB1*13 alleles act by mediating thymic deletion of
a T-cell population that cross-reacts with microbial antigens
and autoantigens [27]. Although the underlying mechanism is
still unproven, these results suggest that the primary influence
of HLA-DRB1 alleles is on the switch from phase C to F, i.e.
the development of disease in the context of ACPA positivity.
Further insight into the genetic associations of RA comes
from the finding that different genetic associations exist ac-
cording to the profile of autoantigens recognised by ACPAs in
a given individual [28]. One weakness of a significant portion
of genetic studies is a failure to define these fine specificities,
instead relying on anti-cyclic citrullinated peptide (anti-CCP)
antibodies as a generic marker of ACPA status. A full under-
standing of the immunogenetics of RA will only be possible
once the pathways leading to antibody reactivity to individual
autoantigens have been defined.
Thus far, the genetic evidence discussed applies only to
seropositive RA. A study of twin pairs with at least one RA
twin has demonstrated that the heritability of ACPA-positive
and ACPA-negative RA is comparable (68 and 66% respec-
tively) [29]. However, HLA SE alleles explained significantly
less of this heritability in ACPA-negative disease (2.4 versus
18%) [29]. As is the case for ACPA-positive disease, there is
an association of ACPA-negative RA with variability at the
HLA loci [30]. Recent work has identified distinct HLA al-
leles associated with seronegative RA [31], which suggests
that the mechanisms underlying its HLA associations may
differ slightly from seropositive disease.
Taken together, current genetic evidence implicates antigen
presentation, either in the thymus or periphery, as a key step in
the aetiology of RA. However, the development of symptoms
depends on further non-heritable pathogenic processes. The
remainder of this review focuses on the putative mechanisms
that promote autoimmunity in genetically susceptible
individuals.
Loss of tolerance to Bself^ peptides
after post-translational modification
In early RA, immune responses have been detected against a
range of peptides/proteins that have undergone specific forms
of post-translational modification. Autoantibodies directed
against peptides/proteins that have undergone citrullination
have been detected up to 9 years prior to the onset of symp-
toms [7, 8], suggesting that the loss of tolerance to citrullinated
peptides/proteins is an early event in the development of RA.
Retrospective analysis shows that epitope spreading follows
loss of tolerance, such that the repertoire of peptides
recognised by ACPAs expands as time to diagnosis decreases
[32]. Furthermore, in a prospective cohort of subjects with
seropositive arthralgia, recognition of multiple citrullinated
peptides correlated with increased risk of developing arthritis
during follow-up [33]. Alongside epitope spreading, the avid-
ity of ACPAs increases from phase C until disease onset, when
no further avidity maturation is observed [34]. Taken together,
these results show that expansion of the immune response
against citrullinated autoantigens is associated with progres-
sion from EULAR phase C to phase F.
A range of inflammatory processes may be responsible for
the generation of these autoantigens. Citrullinated proteins
have been identified in inflamed specimens from a range of
tissue types, suggesting that citrullination may be induced
non-specifically by local inflammation [35]. Various environ-
mental factors may drive such processes, as discussed in detail
in subsequent sections of this review. Smoking is one example
of an environmental risk factor for RA that has been
Semin Immunopathol
specifically linked with citrullination. For example, a study of
specimens from bronchoalveolar lavage found that cells from
smokers had higher expression of citrullinated proteins [36].
This was associated with increased expression of
peptidylarginine deiminase isoform 2 (PAD2), which was
likely responsible for smoking-induced citrullination [36].
One can therefore hypothesise that upregulation of PAD2 in
respiratory mucosa causes local hypercitrullination and that
this provides a source of autoantigens driving the develop-
ment of ACPAs. This effect may explain the epidemiological
observation that smoking is a risk factor for seropositive, but
not seronegative, RA [37]. Interestingly, increased
citrullination has not been observed in whole tissue specimens
from bronchoscopic biopsy or lobectomy [36, 38], raising the
possibility that the effect of cigarette smoke is restricted to the
airspace-facing aspect of the alveolar compartment.
A specific component of the inflammatory response that
may provide a source for citrullinated autoantigens is the
formation of neutrophil extracellular traps (NETs). NETs
are known to contain citrullinated proteins e.g. histone
H1 and H4, presumably due to the action of neutrophil
peptidylarginine deiminase isoform 4 (PAD4) [39].
Indeed, active PAD2 and PAD4 isoforms are released from
NETotic neutrophils in vitro [40]. Citrullinated H4 from
NETs is bound by antibodies from the serum of RA pa-
tients [41], showing that the products of NETosis can be
targeted by ACPAs. Important work by Khandpur and col-
leagues showed that NETosis is enhanced in RA compared
to osteoarthritis and that ACPAs can stimulate NET forma-
tion [42]. Therefore, by externalising citrullinated proteins,
NETs may contribute to the induction and expansion of
autoimmunity in a positive feedback loop [42].
Although the work discussed here primarily concerns
citrullinated autoantigens, there is evidence of autoimmunity
to peptides that have undergone other forms of post-
translational modification. Firstly, a retrospective analysis of
serum samples from a military cohort found that ACarPAs
were associated with future diagnosis of RA [9]. Cross-
sectional data have extended this finding to first-degree rela-
tives of RA patients [43], and it would be informative to study
in more detail the temporal relationship between ACarPA pos-
itivity and symptom onset. Secondly, in patients with early
inflammatory arthritis, detection of antibodies against acety-
lated vimentin was associated with development of RA [5].
Therefore, at least three distinct post-translational modifi-
cations are associated with the early phases of RA develop-
ment. It is not known whether the pathological processes that
drive autoimmunity against these modified peptides are dif-
ferent or if the same underlying mechanism underlies the gen-
eration of all RA-associated antibodies. In addition to being a
marker of RA, loss of tolerance to Bself^ peptides that have
undergone post-translational modifications may contribute to
the pathogenesis of RA.
Evidence for a pathogenic role for RA-related
autoantibodies
Epidemiological evidence has associated ACPA positivity
with increased disease severity, particularly with radio-
graphic progression [44] and all-cause mortality [45].
Such observations have stimulated investigation of the im-
munological and pathological effect of ACPAs in animal
models of RA. Wigerblad and colleagues showed that ad-
ministration of ACPA to mice resulted in IL-8-dependent
pain-like behaviour without any evidence of inflammation
[46]. This raises the possibility that ACPAs may be respon-
sible for inducing arthralgia prior to the onset of joint in-
flammation i.e. that they may precipitate EULAR phase D.
However, it is not clear how well the tests of mechanical/
thermal hypersensitivity and assessment of pain-like be-
haviour used in this murine study recapitulate the symp-
toms experienced by RA patients, and of course not all
patients with inflammatory arthralgia who eventually de-
velop RA are ACPA-positive.
Further work builds on the finding that anti-mutated
citrullinated vimentin autoantibodies induce differentiation
of osteoclasts in vitro and stimulate bone-resorptive activity
[47]. Krishnamurthy and colleagues demonstrated that
polyclonal ACPAs isolated from RA patients induced oste-
oclastogenesis via a PAD-dependent IL-8-mediated auto-
crine mechanism [48]. Furthermore, loss of trabecular bone
mineral density was observed when certain monoclonal
ACPAs were administered to mice. These findings are con-
sistent with imaging evidence from asymptomatic ACPA-
positive human subjects showing reduced bonemineral den-
sity compared to ACPA-negative controls [49]. However,
the dominant feature in humans is thinning and fenestration
of the periarticular cortical bone, with thinning of the tra-
becular bone a milder phenomenon [49]. Therefore, al-
though the evidence provided by Krishnamurthy et al. sug-
gests that ACPAs could be responsible for bone loss in early
RA, it is not clear that the murine process is equivalent to
that in patients.
Thus far, the evidence presented suggests that the effect
of ACPAs could account for some features of phases C–D
of RA development. In addition, there is evidence that
ACPAs could promote other aspects of immune activation
that characterise RA. Firstly, immune complexes contain-
ing citrullinated fibrinogen and ACPAs from RA sera can
induce tumour necrosis factor (TNF) secretion from mac-
rophages [50]. This pro-inflammatory mechanism is medi-
ated by the surface-expressed FcγIIa receptor. Further
in vitro work has demonstrated that such immune com-
plexes can also trigger macrophage TNF production by
co-stimulation of toll-like receptor-4 (TLR-4) and Fcγ re-
ceptors [51]. Finally, purified ACPAs can induce NFκB
activation and TNF production by monocytes in vitro by
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binding to the surface-expressed citrullinated Grp78 recep-
tor [52]. Taken together, these experiments suggest multi-
ple mechanisms by which ACPAs, either alone or as com-
ponents of immune complexes, can stimulate macrophages
to release pro-inflammatory cytokines implicated in RA
pathogenesis.
Recent evidence suggests that glycosylation may regu-
late the pathogenicity of such autoantibodies. Pfeifle et al.
have identified IL-23 and TH17 cells as decisive factors that
promote the intrinsic inflammatory activity of autoanti-
bodies in murine models of autoimmune arthritis [53]. A
retrospective analysis of serum from asymptomatic
ACPA-positive humans (phase C) demonstrated signifi-
cantly reduced glycosylation of ACPAs prior to RA devel-
opment [53]. This study defines an IL-23-TH17 cell-
dependent pathway that could unmask a pre-existing breach
in immunotolerance by downregulating β-galactoside
α2,6-sialyltrasferase 1 activity in newly differentiating
antibody-producing cells [53].
Therefore, there is some experimental support for a path-
ogenic role for ACPAs in early RA. ACPAs may be respon-
sible for some of the symptoms and features of RA devel-
opment and may play a role in driving the inflammatory
process in seropositive disease. Some of this evidence de-
rives from animal models of debatable face validity and
from in vitro cell lines. In future, therapeutic manipulation
of ACPAs during different phases of RA development in
humans could provide valuable insight into their pathogen-
ic role. This may be possible using anti-plasma cell thera-
pies, tolerisation immunotherapy or the development of
novel peptides to antagonise ACPAs [54–56]. If such strat-
egies could prevent transition from at-risk phases to classi-
fiable RA, this would provide stronger evidence that
ACPAs are of pathogenic importance.
The lung mucosa and the development
of autoimmunity
As introduced above, smoking is linked with increased
citrullination in bronchoalveolar lavage (BAL) samples [36].
In early untreated seropositive RA patients, increased local
citrullination has been associated with parenchymal lung ab-
normalities on high-resolution computed tomography
(HRCT) and with high levels of ACPAs in BAL fluid [57].
ACPA levels were higher in BAL fluid than in the serum,
possibly reflecting local autoantibody production by lung tis-
sue [57]. These findings raise the possibility that the respira-
tory mucosa could play a role in the early stages of RA-
associated autoimmunity.
Support for this hypothesis derives from studies of individ-
uals in earlier phases of RA development. For example,
HRCT reveals airway abnormalities in seropositive
individuals who have no evidence of inflammatory arthritis
on clinical examination i.e. from EULAR phase C/D [58].
Important work by Willis and colleagues has demonstrated
the presence of ACPAs/RF in both the sputum of patients with
early RA and the sputum of healthy individuals with either
RA family history or ACPA positivity [59]. In these at-risk
subjects, the ratio of autoantibody to total immunoglobulin
was higher in sputum than in serum [59]. Furthermore, in a
subset of at-risk individuals, autoantibodies were present in
sputum but absent in serum [59], indicating that autoanti-
bodies are either generated or sequestered in lung tissue.
Taken together, these results suggest either that the lungs are
an early target for injury secondary to autoimmunity or that
they are implicated in its development.
In this context, a case-control study identified an associ-
ation between bronchiectasis, cystic fibrosis and anti-CCP
positivity [60]. This is significant because it is consistent
with the hypothesis that respiratory mucosal inflammation
per se can induce ACPA production. However, prospective
studies remain necessary to determine the temporal rela-
tionship between ACPA positivity and respiratory mucosal
inflammation.
In addition, there is histological evidence of germinal cen-
tre formation and B-cell/plasma cell accumulation in bronchi-
al biopsies from ACPA-positive patients with recent onset of
RA [61]. This suggests that bronchial tissue is a site of anti-
body production, but does not itself directly imply generation
of RA-related autoantibodies. It would be valuable to investi-
gate the association between these histological features and
the local levels of ACPAs. Replication of these results in
pre-symptomatic ACPA-positive individuals, ideally with
follow-up to identify development of classifiable RA, would
strengthen the concept that lung-derived ACPAs play a path-
ogenic role in RA.
If autoantibodies are generated in the lung, it is plausible
that they could cross-react with autoantigens in the synovium.
Support for this comes from the proteomic identification of
shared citrullinated peptides, in particular of citrullinated
vimentin, from bronchial and synovial tissue in RA [62].
This finding is significant because citrullinated vimentin has
previously been validated as a target for ACPAs [63]. Thus,
inflammation-induced autoantibody production by lung tissue
may directly contribute to the development of arthritis.
In summary, there is strong evidence for lung involvement
early in RA and emerging indirect evidence for a role in gen-
erating RA-associated autoantibodies. Common citrullinated
antigenic targets in the lung and joint tissue provide a plausi-
ble mechanism by which autoantibodies from the lung could
promote joint disease. However, it is not yet known whether
the processes described here actually contribute to, or are nec-
essary for, the development of clinical arthritis. Finally, none
of the evidence discussed here is applicable to the pathogen-
esis of seronegative RA.
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Periodontal tissue in pre-symptomatic rheumatoid
arthritis
In addition to lung tissue, periodontal tissue has attracted sub-
stantial interest as a potential site for the initiation of autoim-
munity associated with RA. This was stimulated by two ob-
servations. Firstly, the prevalence of RA is significantly in-
creased in patients with periodontitis [64]. Secondly, in
established RA, periodontitis has been correlated with positiv-
ity for ACPAs [65] and with increased disease activity [66].
These studies support a link between periodontitis, autoanti-
body status and RA, but do not establish a causal relationship.
A clue to a possible underlying mechanism for this associ-
ation comes from studies of inflamed periodontal tissue.
Inflamed periodontium expresses increased levels of PAD en-
zymes and citrullinated proteins [67], and anti-CCP antibodies
have been detected in the gingival crevicular fluid of peri-
odontitis patients [68]. This effect may be explained by the
properties of the periodontal pathogen Porphyromonas
gingivalis. P. gingivalis possesses a PAD enzyme that is capa-
ble of citrullinating fibrinogen and α-enolase, both of which
are potential targets for ACPAs [69]. Indeed, in individuals
with genetic risk factors for RA, antibodies to P. gingivalis
have been associated with systemic RA-related autoantibodies
[70, 71]. More recently, it has been shown that P. gingivalis
PAD can undergo autocitrullination and that antibodies direct-
ed against this citrullinated form of PAD are more prevalent in
RA patients compared to controls [72]. However, an antibody
response to citrullinated PAD peptides was not found in indi-
viduals who later developed RA, suggesting that these anti-
bodies are unlikely to play an aetiological role [73].
Taking the above together, it has been hypothesised that
P. gingivalis is responsible for the induction of RA-
associated autoimmunity in a subset of individuals. One pre-
diction of this is that the prevalence of P. gingivalis would be
higher in patients with new-onset RA than in healthy controls.
However, this has not been shown [74], and one study found
reduced prevalence of P. gingivalis in salivary samples from
such patients [75]. There are a number of possible explana-
tions for this finding. Firstly, P. gingivalismay not have a role
in the aetiology of RA or the induction of ACPAs. Secondly,
there may be additional factors other than the prevalence of
P. gingivalis that modulate the host immune response and thus
the likelihood of developing autoimmunity. It is also plausible
that an immune response to P. gingivalis that cross-reacts with
autoantigens could be effective at reducing its carriage.
Prospective studies will help to clarify the relationship be-
tween P. gingivalis and RA-associated autoimmunity.
More broadly, metagenomic shotgun sequencing of sali-
vary and dental samples has detected oral dysbiosis in RA
patients [75]. However, because this study was cross-
sectional in design, we cannot infer the chronology of these
changes and the direction of causality is unclear. Again, a
prospective study of individuals in phases A and B of RA
development would shed some light on this.
Taken together, current evidence shows that the oral
microbiome in RA is different to that observed in healthy
controls. This may play a role in the development of autoim-
munity, or it may simply be a consequence of the disease.
Periodontal inflammation is associated with the presence of
RA-related autoantibodies, but the aetiological significance of
this is also unclear. Even if a causal link were to be established
between periodontitis and RA, this would most likely account
for the development of RA in only a subset of seropositive
patients. Therefore, other tissues outside the oral cavity are
likely to play a significant role.
The intestinal microbiota in pre-symptomatic
rheumatoid arthritis
The concept that the intestinal microbiota plays a role in the
immunopathology of inflammatory arthritis is supported by
experiments using the k/BxN mouse model. This mouse ex-
presses both a T-cell receptor transgene and the MHC class II
molecule Ag7 and develops inflammatory arthritis associated
with anti-glucose-6-phosphate isomerase (anti-GPI) autoanti-
bodies [76]. Wu and colleagues showed that the development
of arthritis could be prevented by raising the mouse in a germ-
free environment and could be restored by exposure to a single
gut commensal bacterium Candidatus Savagella [77]. This
process correlated with germinal centre formation, anti-GPI
abundance and restoration of splenic TH17 populations in an
IL-17-dependent manner [77]. In humans, certain bacteria,
such as Prevotella copri, are more abundant in stool samples
from new-onset RA patients than healthy controls [78].
Colonisation of mice with P. copri renders them more sensi-
tive to chemically induced colitis [78], indicating that the bac-
terium has pro-inflammatory properties. Therefore, it is plau-
sible that the composition of the intestinal microbiota could
predispose to RA by inducing a pro-inflammatory state.
To further explore the role of intestinal dysbiosis in pre-
disposition to arthritis, Maeda and colleagues inoculated
faecal samples from early RA patients into germ-free ar-
thritis-prone mice [79]. When treated with zymosan, these
mice showed increased intestinal TH17 cells and more se-
vere clinical arthritis scores [79]. A role for P. copri is
suggested by the finding that dendritic cells exposed to
the bacterium stimulated naïve T-cells from arthritis-prone
mice to produce IL-17 in response to an autoantigen [79].
In addition, Pianta and colleagues identified subgroups of
new-onset RA patients with differential IgA or IgG reactiv-
ity to an HLA-DR-presented peptide from P. copri. [80].
This reactivity appears to be specific to RA patients and
correlates with TH17-weighted versus Th1-weighted im-
mune responses. [80]. Intriguingly, patients with an IgA-
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dominant TH17-weighted response were more likely to dis-
play ACPA positivity than those with IgG-dominant Th1-
weighted responses to P copri. Therefore, this study sug-
gests that P. copri may influence ACPA production as well
as the release of pro-inflammatory cytokines such as IL-17
by T-cells.
Although P. copri has attracted specific attention in this
field, metagenomic shotgun sequencing has revealed a
broader pattern of intestinal dysbiosis associated with RA
[75]. In particular, Haemophilus species are depleted and
Lactobacillus species over-represented in stool samples from
RA patients [75]. It is not knownwhether this is a contributing
factor to the development of RA or an effect of the disease.
Notably, the prevalence of Haemophilus species negatively
correlated with autoantibody levels, suggesting that the bacte-
ria may play a protective immune-modulating role. Therefore,
dysbiosis could predispose to RA due to both the overgrowth
of pro-inflammatory species and the depletion of protective
species that possess immunomodulatory functions. By a
mechanism currently undetermined, treatment with a
disease-modifying anti-rheumatic drug (DMARD) appears
to partially restore the microbiome to a healthy state [75].
The hypothesis that intestinal dysbiosis contributes to RA
pathogenesis has led to small-scale randomised studies of pro-
biotic therapy for patients with established disease. These
have demonstrated some clinical improvement with probiotic
therapy, which is accompanied by a reduction in serum levels
of certain pro-inflammatory cytokines [81, 82]. Such findings
are consistent with the principle that the intestinal microbiota
can influence RA by altering the balance of pro- and anti-
inflammatory factors. Therapeutic approaches to the manipu-
lation of the microbiota in individuals at risk of developing the
disease would aid the evaluation of this hypothesis.
In summary, as in the oral cavity, the flora of the intestine is
altered in RA compared to healthy individuals. Experimental
evidence suggests that certain commensal bacteria can have
systemic pro-inflammatory effects, and it is possible that
others modulate the immune system to counteract this. RA-
specific immune responses to commensal bacteria have been
identified, suggesting they may have immunopathological
significance. A major limitation of the studies discussed here
is the use of samples from patients with classifiable disease,
rather than subjects at risk of future RA. To determine the role
that the intestinal microbiota may play in the aetiology of RA,
prospective studies of individuals from EULAR phases A–C
will be required.
Dysregulation of anti-inflammatory
and pro-resolution signalling pathways
Thus far, this review has largely discussed pro-inflammatory
mechanisms that are thought to contribute to the development
of pre-symptomatic autoimmunity in RA. However, there is
increasing interest in anti-inflammatory pathways whose sup-
pression may facilitate autoimmune disease. Here, we review
evidence for dysregulation of anti-inflammatory lipid media-
tors and cholinergic signalling.
Firstly, the involvement of lipid signalling in RA develop-
ment has emerged since early studies showed that omega-3
fatty acid supplementation could reduce symptoms in patients
with classified RA [83]. This could potentially be explained
by increased levels of anti-inflammatory eicosanoid-derived
resolvins, as has been observed in plasma following omega-3
fatty acid supplementation [84]. Therefore, recent work has
aimed to elucidate the role of resolving signalling in murine
models of inflammatory arthritis.
For example, in the k/BxN model, administration of
arthritogenic serum results in reduced local levels of pro-
resolving lipid mediators in the arthritic joint [85].
Subsequently, D-series resolvins RvD1, RvD2 and RvD3 are
upregulated during the resolution phase [85]. When resolution
is delayed by a second serum challenge, levels of RvD3 are
reduced suggesting that non-resolving inflammation is asso-
ciated with dysregulated resolvin signalling [85]. In line with
this hypothesis, serum levels of RvD3 are significantly re-
duced in RA patients compared to healthy controls [85].
Whether this is also true for at-risk individuals prior to RA
development is not known. It would be informative to mea-
sure resolvin levels locally in human joints and to prospective-
ly determine when this dysregulation occurs.
In the same k/BxN model, treatment with RvD1 reduced
both clinical arthritis scores and leukocyte infiltration within
the synovium [86]. Consistent with this, RvD1 and RvD4
isolated from human synovial fluid were both shown to reduce
neutrophil migration to an IL-8 gradient in vitro [86].
Therefore, dysregulation of pro-resolving lipid mediators in
RA could result in disinhibition of neutrophil chemotaxis,
predisposing to chronic inflammation. This process may be
especially relevant to the transition from early synovial in-
flammation to classifiable RA.
It has also been suggested that autonomic anti-
inflammatory signalling is disrupted in RA. Koopman and
colleagues recently demonstrated that resting heart rate
(HR) was elevated prior to the onset of disease in individ-
uals at risk for developing RA [87]. This is thought to reflect
reduced vagal parasympathetic tone and was associated
with increased risk for developing RA during follow-up
[87]. A potential mechanism by which reduced parasympa-
thetic activity could predispose to RA is suggested by the
finding that individuals with higher resting HR had lower
expression of the α7 nicotinic acetylcholine receptor
(α7nAChR) on peripheral blood monocytes [87].
Activation of the α7nAChR has previously been shown to
reduce secretion of pro-inflammatory cytokines by CD4+ T-
cells and macrophages [88, 89]. Therefore, reduced
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activation of the cholinergic anti-inflammatory pathway
could contribute to the pathogenesis of RA. However, the
use of cardiac vagal tone as a surrogate marker for activity
of the cholinergic anti-inflammatory pathway is controver-
sial as the neuroanatomical basis for this pathway has not
been elucidated [90]. Furthermore, it is possible that in-
creased resting HR and reduced α7nAChR expression are
consequences of early inflammatory processes rather than
reflective of an underlying causal mechanism.
On the other hand, vagal stimulation in humans has been
shown to reduce peripheral blood levels of TNF, IL-1β and
IL-6 and to improve RA clinical disease severity scores in a
non-placebo-controlled study [91]. Further randomised stud-
ies are required to confirm this finding. It would be interesting
to study whether vagal stimulation could prevent the onset of
RA in patients at risk for the disease. There are of course
ethical barriers to performing such invasive procedures in
healthy individuals, but these may be surmountable if their
quantifiable risk of RA can be determined to be sufficiently
high.
In summary, there is increasing focus on the contribution of
dysregulated anti-inflammatory pathways to the pathogenesis
of RA. Further work in human subjects is required to define
these pathways and determine the nature of their dysregulation
in pre-symptomatic individuals.
Changes in lymphoid tissue preceding the onset
of rheumatoid arthritis
Dysregulation of the balance between pro-inflammatory and
anti-inflammatory cytokine production has also been ob-
served in lymphoid tissue. The study of lymphoid tissue prior
to the onset of RA has been facilitated by development of a
needle-core inguinal lymph node biopsy technique [92, 93].
This allows lymph node tissue from individuals at risk of RA
to be analysed using flow cytometry and transcriptional pro-
filing. The first exploratory study to use these methods found
an increased frequency of CD19+ B-cells in early arthritis
compared to healthy controls, with a non-significant trend
towards a similar increase in autoantibody-positive at-risk
subjects [93].
This technique has subsequently been used in larger popu-
lations to characterise changes to CD4+ T-cells, CD8+ T-cells
and innate lymphoid cells (ILCs). This demonstrated reduced
frequencies of IL-4- and IL-10-secreting CD4+ T-cells in lym-
phoid tissue from at-risk seropositive individuals [94]. Such
reduction in regulatory cytokine production may explain the
observation that the pro-inflammatory TH1 phenotype was
more common among CD4+ T-cells from early RA patients
[94]. Furthermore, in at-risk subjects, there was a reduced
frequency of double-positive IFNɣ/IL-10 and IL-17/IL-10 T-
cells in the lymph node. This may represent impaired
autoregulation of pro-inflammatory signalling by CD4+ T-
cells in early phases of RA development [94]. Interestingly,
there was reduced production of IFNɣ and IL-17 by CD4+ T-
cells in an in vitro stimulation assay, possibly reflecting T-cell
exhaustion secondary to sustained autoantigen exposure [94].
In the context of CD8+ T-cells, the assessment of inguinal
lymph node tissue demonstrated increased populations of
CD45RO+ memory cells and recently activated CD69+ cells
in both at-risk and early RA patients [95]. Analogous to find-
ings from CD4+ T-cells, in vitro stimulation assays were sug-
gestive of CD8+ T-cell exhaustion [95]. Of interest, this study
also demonstrated a decreased frequency of regulatory CD8+
IL-10+ T-cells in peripheral blood from early RA patients
[95], reinforcing the role of immunoregulatory dysfunction
in early disease.
Recently, needle-core lymph node biopsy has been used to
investigate innate lymphoid cell (ILC) subsets in RA devel-
opment [96]. Lymphoid tissue inducer (LTi) cells play an im-
portant role in the development of lymph nodes and were
progressively reduced in seropositive at-risk individuals and
RA patients compared to healthy controls [96]. The authors
speculate that reduction in this cell count could reflect im-
paired lymph node remodelling. In addition, the IFNɣ-produc-
ing ILC1 population was increased in at-risk subjects and
early RA patients, and the IL-17-producing ILC3 population
was increased in early RA [96]. Both of these cell types are
potentially pro-inflammatory, suggesting that early develop-
ment of RA is characterised by a shift of the ILC population
towards an activated rather than homeostatic phenotype.
However, the functional implications of these changes
in vivo are unclear.
The studies discussed here provide new insights into
changes within lymphoid tissue associated with phases C–E
of RA development. Taken together, they suggest a dysregu-
lation of lymphocyte function and an early bias towards pro-
inflammatory phenotypes. However, this work is limited by
practical difficulties in obtaining lymph node biopsies from
large numbers of patients and healthy individuals.
Longitudinal follow-up would be useful to determine whether
particular features of lymphoid tissue are associated with fu-
ture progression to RA.
The transition from pre-symptomatic autoimmunity
to the development of joint symptoms
This review has mostly focused on mechanisms outside joint
tissue which may contribute to the development of pre-
symptomatic systemic autoimmunity. For the transition from
phases A–C to phases D–F, there must be additional mecha-
nisms by which systemic autoimmunity begins to affect the
joints. A number of possibilities have been suggested.
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Firstly, it has been demonstrated that identical antigenic
targets exist at mucosal sites where tolerance might be broken
and at synovial tissues [62]. Therefore, antibodies directed
against mucosal neoantigens could cross-react with synovial
peptides and thus promote arthritis. This mechanism does not
explain the delay between initial ACPA positivity and symp-
tom onset, although there may be a small subgroup of patients
in whom symptoms develop without this delay. In this puta-
tive population, induction of cross-reactive autoantibodies
could cause rapid symptom development. Furthermore, IL-
23/TH17-mediated downregulation of antibody glycosylation
may represent a delayed event that induces pathogenicity of
pre-existing cross-reactive autoantibodies [53].
Alternatively, epitope spreading could account for a process
by which tolerance is lost to one autoantigen at a mucosal site,
leading to the development of autoantibodies to a slightly dif-
ferent antigen at the synovium. Prior to the onset of RA, epitope
spreading and avidity maturation occur, so that ACPAs pro-
gressively recognise more fine specificities and bind to
autoantigens with higher avidity [34, 97]. However, only min-
imal further epitope spreading and avidity maturation is ob-
served after diagnosis of RA [34, 97]. We can speculate that
this represents a threshold effect, with clinical disease develop-
ing only once the ACPA response has matured sufficiently.
Thirdly, the existence of circulating immune complexes
containing citrullinated autoantigens could provide a mecha-
nism by which autoantibodies cause joint symptoms. Immune
complexes containing citrullinated fibrinogen co-localise with
complement component C3 in the rheumatoid synovium and
are capable of stimulating macrophages via multiple receptors
[50, 51, 98]. The preferential localisation of immune com-
plexes to the joint could be explained by the specificities of
constituent autoantibodies and potentially by local features of
the synovial vasculature [99].
Furthermore, many processes discussed in this review like-
ly combine to alter the balance between pro-inflammatory and
anti-inflammatory signals in a manner that is permissive for
arthritis development. Factors that contribute to this may in-
clude overgrowth of pro-inflammatory bacteria in the gastro-
intestinal tract, dysregulated autonomic signalling, aberrant
anti-inflammatory lipid pathways and a bias towards TH1
and TH17 differentiation. These immunological mechanisms
are likely to interact with additional environmental factors, for
example trauma [100], to promote the development of early
joint symptoms.
An important prospective study by de Hair and colleagues
used MRI and mini-arthroscopic synovial biopsy to define
features of the synovium in seropositive individuals without
clinical arthritis [12]. In most individuals, there was no signif-
icant subclinical synovitis and no clear association between
the presence of inflammatory cells and subsequent develop-
ment of arthritis [12]. This implies that subclinical inflamma-
tion is not a characteristic feature of at-risk phases of RA
development prior to phase E, although there was a non-
significant trend towards an association between synovial
CD3+ T-cell numbers and later progression to arthritis [12].
One caveat to this conclusion is that it depends on results from
biopsies of the knee, which is not typically one of the first
joints to be affected in RA.
On the other hand, de Hair and colleagues found that the
presence of synovial CD8+ T-cells was associated with the
presence of specific ACPAs and with the total number of
ACPAs detected [12]. Thus, there may be a role for CD8+
T-cells directed against citrullinated peptides in the joint, but
there was no statistically significant association between the
presence of these cells and development of RA. The function
of this synovial CD8+ T-cell population is an important topic
for future research. This may provide new insight into mech-
anisms underlying the development of arthralgia and then
clinically apparent synovitis in seropositive individuals.
Conclusion
Here, we outline the mechanisms that are likely to contribute
to pre-symptomatic autoimmunity associated with RA. In se-
ropositive disease, there is clear evidence for autoimmunity
directed against Bself^ peptides that have undergone specific
forms of post-translational modification. This phenomenon
may be triggered by non-specific local inflammatory process-
es outside the joints, for example in the respiratory mucosa.
There is also some evidence for a role for microbial molecular
mimicry and cross-reactive antibody responses.
In addition, this review considers multiple mechanisms by
which pro- and anti-inflammatory factors become dysregulat-
ed, which may promote both the development of autoimmu-
nity and subsequent progression to clinical disease. These in-
clude dysbiosis of the gastrointestinal tract, altered lipid sig-
nalling pathways and aberrant T-cell differentiation in lym-
phoid tissue.
A major limitation of the literature is its focus on autoanti-
bodies with limited understanding of their pathogenic role.
These autoantibodies have great utility as diagnostic markers
and for easily defining cohorts of individuals at risk for RA.
While there is some evidence indicating that ACPAs may
contribute to disease development, their role in RA pathogen-
esis is not clear. The importance of the autoantibody response
will not be fully understood until it can be manipulated in
humans for prophylactic and therapeutic studies.
Because these autoantibodies are so useful in defining co-
horts of Bat-risk^ individuals, seronegative RA has been rela-
tively understudied. Themajority of research discussed here is
applicable only to seropositive disease, and there is very little
understanding of the immunopathology underlying seronega-
tive RA. This is important because seronegative disease is
likely to be distinct in its aetiology.
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The question posed by this review, Bwhen does the dis-
ease start?^ has no single simple answer. The EULAR ter-
minology for stages of RA development forms a useful
conceptual framework around which we have structured
our thinking. Accordingly, we propose a model in which
multiple Bswitches^ are required for the development of
RA, analogous to Knudson’s multiple-hit hypothesis of on-
cogenesis [101]. The first stage is genetic susceptibility,
which is then augmented by environmental risk factors that
act to promote inflammation. These may include smoking,
trauma and microbiological factors.
Arguably, the acquisition of hereditary risk factors at con-
ception represents the Bstart^ of RA pathogenesis, but this is
not conceptually useful because the disease is multifactorial.
Alternatively, given that many individuals in phases A–C nev-
er develop RA, we might consider the onset of symptoms to
be the start of disease. However, by this point, the underlying
immunopathology may be well-established. Therefore, there
is no individual stage that we define as the start of disease, and
it is better considered as a prolonged process characterised by
multiple superimposed switches. Nevertheless, this is an ex-
tremely important question for future scientific and clinical
research. In particular, if we better understand the mechanisms
of pre-symptomatic autoimmunity and the switches that trig-
ger the transition between different phases of RA develop-
ment, we may be able to modulate these for clinical benefit.
This raises the possibility of future prophylactic interventions
for individuals who can be identified as high risk for RA.
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